Completed NCT00277667
This summary needs review. Please check the official study record and contact the research team for details.
In Cincinnati Bipolarity Drug i A study involving a medication or substance. Over 18 Years
Countries United States
Sponsor Lindner Center of HOPE
Condition Bipolarity Completed NCT02488109
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Palo Alto Eating disorders Other From 12 Years to 24 Years
Countries United States
Sponsor University of California, San Francisco
Condition Eating disorders Completed NCT00822601
This summary needs review. Please check the official study record and contact the research team for details.
In Paris OCD Device i A study involving a tool, app, wearable, test, or medical device. From 18 Years to 65 Years
Countries France
Sponsor Assistance Publique - Hôpitaux de Paris
Condition OCD Completed NCT01940939
This summary needs review. Please check the official study record and contact the research team for details.
In Shanghai Schizophrenia Device From 20 Years to 49 Years
Countries China
Sponsor Shanghai Mental Health Center
Condition Schizophrenia Completed NCT03818971
This summary needs review. Please check the official study record and contact the research team for details.
In Laxou Addiction Other From 18 Years to 35 Years
Countries France
Sponsor Centre Psychothérapique de Nancy
Condition Addiction Completed NCT00277654
This study is completed in the United States. It is testing risperidone Monotherapy for anxiety.
In Cincinnati Bipolarity, Anxiety Drug Over 18 Years
Countries United States
Sponsor Lindner Center of HOPE
Condition Bipolarity, Anxiety Completed NCT03485287
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Vancouver PTSD Behavioral Over 18 Years
Countries Canada
Sponsor Resilient Pharmaceuticals
Condition PTSD Withdrawn NCT04968938
This summary needs review. Please check the official study record and contact the research team for details.
Location not clearly listed PTSD Behavioral Over 18 Years
Countries
Sponsor Resilient Pharmaceuticals
Condition PTSD Completed NCT03249857
This study exists to see whether the medication Sensorimotor can play a useful role in care. Researchers are trying to understand whether the medication Sensorimotor can improve attention, thinking, or day-to-day functioning.
In Saint-Etienne Bipolarity Behavioral From 18 Years to 55 Years
Countries France
Sponsor Centre Hospitalier Universitaire de Saint Etienne
Condition Bipolarity Completed NCT00932204
This summary needs review. Please check the official study record and contact the research team for details.
In Seoul OCD Behavioral From 19 Years to 60 Years
Countries South Korea
Sponsor Severance Hospital
Condition OCD Completed NCT00711269
This study exists to compare options and see whether the medication SM-13496 offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
Multiple locations, including Tokyo, Etc. Schizophrenia Drug From 18 Years to 74 Years
Countries Japan, South Korea, Taiwan
Sponsor Sumitomo Pharma Co., Ltd.
Condition Schizophrenia Active Not Recruiting NCT06442462
This study is comparing SPG302 with placebo for people with Schizophrenia. Participants receive SPG302 or placebo and complete study visits and assessments.
Multiple locations, including Garden Grove Schizophrenia Drug From 18 Years to 65 Years
Countries United States, Australia
Sponsor Spinogenix
Condition Schizophrenia